在缺血性中风患者中,JAK2V617F突变非常普遍:一项病例对照研究
Marie Hvelplund Kristiansen1,2, Lasse Kjær3, Vibe Skov3
1Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
在缺血性中风患者中,JAK2V617F基因突变比一般人群中更为普遍,这表明它是新的脑血管风险因素. 这种关联在现有吸烟者中尤为明显.
科学领域:
- 遗传学 是一个遗传学.
- 神经学 神经学
- 心脏病学 心脏病学
背景情况:
- 缺血性中风的复发率很高,需要识别新的风险因素.
- 在总人口的3.1%中存在的JAK2V617F基因突变是潜在的,但尚未研究的脑血管风险因素.
研究的目的:
- 为了调查JAK2V617F突变在丹麦缺血性中风患者中与匹配的对照组相比的流行率.
- 确定JAK2V617F突变是否是缺血性脑血管疾病 (ICVD) 的独立风险因素.
主要方法:
- 一组538名连续的丹麦缺血性中风患者 (7天内出现症状) 与来自丹麦一般郊区人口研究的年龄和性别匹配的对照进行了比较.
- 滴滴数字聚合酶链反应 (ddPCR) 用于分析患者和对照组中JAK2V617F突变的DNA.
- 用多重调整的条件后勤回归分析来评估JAK2V617F和ICVD之间的关联,并对脑血管并发症进行调整.
主要成果:
- 在11.3%的缺血性中风患者中发现了JAK2V617F突变,而在匹配对照中为4.4%.
- 经过风险因素调整后,缺血性中风患者携带JAK2V617F突变 (OR,2.37;95% CI,1.57-3.58;P <.001) 的可能性增加了2.37倍.
- 在目前吸烟者中,JAK2V617F与缺血性中风之间的关联显著更强 (OR,4.78;95% CI,2.22-10.28;P <.001).
结论:
- JAK2V617F突变是一种新的,重要的缺血性中风风险因素.
- 识别和管理JAK2V617F可能为预防中风提供新的治疗策略,特别是在吸烟者中.
更多相关视频
07:17Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
相关概念视频
The JAK-STAT Signaling Pathway
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
